Day Traders, Penny Stocks, Stock Options, Futures and Forex

USDA approval for Econiche (E.coli Vaccine) & Urocidin (Bladder Cancer) Phase 3 results in 3Q 2010 !! Bioniche has tremendous upside Potential .Please do your own Homework. Good Luck to All !!!!!!

Bioniche Life Science (BNC.TO) !!!

Market Cap: 74,6 Mio $
Cash: 22 Mio $
Price: 1,03 $


Buy rating by Dundee Sec (June 2010)....

Bioniche has three businesses with diversified risk/reward profiles:Animal Health, which is expected to generate around $28 million in salesin fiscal 2010; Human Health, with Phase 3 results expected in mid-2010from lead product, Urocidin, testing for bladder cancer; and FoodSafety, with Canadian approval and a conditional license pending in theU.S. of a vaccine for reducing E. coli 0157 in cattle feces, and apipeline of other vaccines.

Mr. Martin points out that Urocidin provides the “biggest upsidepotential” for Bioniche investors. His initial diligence suggests thatUrocidin has a “relatively high overall probability of approval,” eventhough the first of two planned Phase 3 trials has a moderate level ofrisk, as the refractory patients enrolled in the trial are a“tougher-to-treat” population than was enrolled in the Phase 2 trial, hesays.

Mitigating the risk somewhat is the 20% “complete response” hurdlerequired for Phase 3. That compares with the company’s Phase 2 results,where patients achieved a 46.4% CR rate at 26 weeks in a population thatwas mainly relapsed but also included a few patients being treated forthe first time.

A second planned Phase 3 trial will test Urocidin head-to-head againstthe current standard of care, baccilus Calmette-Guerin (BCG) infirst-line treatment, “where we expect Urocidin to demonstrate betterefficacy, based on prior data, and superior safety and tolerability,” hepredicts.

In 2009, Bioniche licensed Urocidin’s U.S. commercial rights to EndoPharmaceuticals. Based on incidence of bladder cancer and possiblepricing, he figures the global market opportunity for Urocidin in therefractory population could be $800 million. If the second Phase 3 trialexpands the Urocidin label to first-line treatment, the marketopportunity could grow to an estimated $2 billion.

“Twenty-five percent penetration of this market would represent $500million in annual sales and an estimated $112.5 million in gross profitfor Bioniche,” Mr. Martin says .

--------------------------------------------------------------------

Bioniche to Get up to $130M in Urology Deal with Endo
BioWorld Today


Crystal Research 18.02.2010
http://www.crystalra.com/pdf/BNC_2QF...e_02-18-10.pdf



Some Positive Signs ..

UPDATE 1-Bioniche gets $6 mln milestone payment from Endo Pharma
UPDATE 1-Bioniche gets $6 mln milestone payment from Endo Pharma | Reuters
---


Bioniche obtains two additional milestones under licensing agreement with Endo
Online Stock Trading Investing Day Trading | TradingMarkets.com
dditional-milestones-under-licensing-agreement-with-endo-777521.html
--


All DMC (Data Monitoring Committee) are Positive !!!!

Bioniche Phase III Clinical Trial With Urocidin(TM) Given Continued Green Light By DMC
Bioniche Phase III Clinical Trial With Urocidin(TM) Given Continued Green Light By DMC



Only 105 patients in current PIII !!!!

In November 2008,
during a meeting of urologists in Santigo Chile, the biopharmaceutical research company presented positive clinical studies (one and two) involving 130 bladder cancer patients treated with Urocidin. Elderly patients (average 73 years old) during the clinical studies noted excellent safety results .



Upcoming Milestones 2010

2009/2010 Conditional license for E. coli cattle vaccine in the U.S.

2009/2010 Achievement of pre-commercialization milestone payments for
UrocidinTM

2010 First U.S. sales of E. coli cattle vaccine

2010 Results of refractory Phase III bladder cancer trial

2011 Belleville, ON vaccine manufacturing centre operational

------------------------------------------------------------------------

Huge bid order at $1,04 , 60k bidder at $1,04 .Good news could be coming .glta

Bioniche is ready to takeoff
BNC.TO | Stock Trader's Cheat Sheet for Bioniche Life Scie Com Npv


BNC.TO - SharpCharts Workbench - StockCharts.com

Presentation
http://www.bioniche.com/pdf/blsi-agm-11-05-09.pdf

Good News is Coming soon .....

about urocidin ..12 min 30 sec+ ..listen
http://webcastingplayer.corporate-ir.net/player/playerHOST.aspx?c=123046&EventId=3228838&StreamId=1530678&TIK={e045afef-fae6-4f6c-bb2c-289b145e1274}&RGS=3&IndexId=


This may not be a perfect transcript but its about that:

"...we are preparing to initiate a launch study with Urocidin in the second half that could become the ??? study of this very interresting product to treat bladder cancer

Urocidin is anovel treatment for refractory bladder cancer which represents the kind of innovative solution we want
to offer to urologist and their patients

As stated earlier we are committed to bladder cancer as an area of therapy to focus as we look to enhance
the range of solutions we can offer to urologist

We carry evaluating data of the first phase III of Uropcidin and expect to finish analysis this quarter prior
to initiating the second phase III study."



---> I cannot see better comments that those of the first 3 phrases considering they got data since +- April and that ata analysis is almost completed.

(1) no reason to prepare the launch of the second Phase III if data of the first phase III are not good
(2) no reason to even mention this second Phase III is data are not good
(3) why would he say that Urocidin "represents the kind of innovative solution..." if data are not good
(4) why say that..."we are committed to bladder cancer as an area of therapy to focus as we look to ** enhance
the range of solutions ** we can offer to urologist ... " while talking about Urocidin if data are not good
(5) finish those comments on Urocidin by repeating that they will launch the second Phase III


Impossible to see any thing negative in those comments, nothing that can prepare investors to a possible failure

3 x Buy Rating
Stock Quote News - Stock Market Quotes, Online Stock Quotes, India

1 x Strong Buy Rating
Best-Rated Canadian Stocks (Aug 1, 2010) - NASD100.com - Daily Stock Rankings

Best-Rated Canadian Stocks (Aug 1, 2010)

Best-Rated S&P 500 Stocks; Highest-Upside; Fastest-Growing; Highest Short Interest
TOP 10 Lists; Up on Unusual Volume; Down on Unusual Volume; 52-Week Highs; 52-Week Lows

Below are the best-rated Canadian stocks based on average Wall Street analyst ratings. Each analyst rating is assigned a number ranging from 1 to 5, with 1 being the highest rating (STRONG BUY) and 5 being the lowest rating (STRONG SELL). Then the average is calculated to represent the overall rating of a stock.

Ranking | Company (Ticker) | Average Rating Value | Average Rating
1 AlarmForce Industries (TSE:AF) 1.00 Strong Buy
2 Altius Minerals Corporation (TSE:ALS) 1.00 Strong Buy
3 Amorfix Life Sciences Ltd. (TSE:AMF) 1.00 Strong Buy
4 Aquila Resources Inc. (TSE:AQA) 1.00 Strong Buy
5 Aeroquest International Limited (TSE:AQL) 1.00 Strong Buy
6 Bioniche Life Sciences (TSE:BNC) 1.00 Strong Buy <<<<<<<<<<<<<<<<<<<<<<<<<<<<<<


Only 100 shares short = GOOD SIGN
The Stock Market, Canadian Stock Exchange | TMX Group

Could it be the day we are all hoping for?

The next conference on the 12th could help us to get some more insights on MCC

If they repeat what they said on the last CC, if we can feel they are optimistic, confident, then... MCC could explain at least in part the up trend since last June


Endo to Present at the Bank of AmericaMerrill Lynch 2010 Specialty Pharmaceuticals Conference

Friday, August 06, 2010

CHADDS FORD, Pa., Aug.6 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP)today announced that it will present at the Bank of America Merrill Lynch 2010Specialty Pharmaceuticals Conference onThursday,August 12, 2010, at 8:00 a.m. EDT. Alan Levin, executive vice president and chief financial officer ofEndo, will review the company's productsand development programs.

The presentation will be webcast live and can be accessed from Endo'swebsite at Endo Pharmaceuticals under theinvestors section.

Good News .. Load up the truck before its too late !!!!

Additional Phase III clinical trial with Urocidin(TM) expected to commence in 2010

Press Release Source: Bioniche Life Sciences Inc. On Thursday August 19, 2010, 7:00 am

- analysis of data from first Phase III clinical trial nearing completion -
BELLEVILLE, ON, Aug. 19 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC - News), a research-based, technology driven Canadian biopharmaceutical company, today provided an update on the clinical development program for its proprietary product for non-muscle-invasive bladder cancer - Urocidin(TM).

Bioniche and its development partner, Endo Pharmaceuticals Inc. (NASDAQ: ENDP - News), are in the process of finalizing a protocol for an additional clinical trial - expected to begin enrolling patients in 2010. Details of this new protocol, when finalized, will be made publicly available via the U.S. National Institutes of Health clinical trial registration service at Home - ClinicalTrials.gov.

"We're preparing to initiate a large study with Urocidin in the second half of this year that could become the pivotal study of this very interesting product to treat bladder cancer," said Dr. Ivan Gergel, Executive Vice President, Research and Development at Endo Pharmaceuticals Inc. "Urocidin is a novel treatment for refractory bladder cancer, which represents the type of innovative solutions we want to offer urologists and their patients."

Concurrently, 12-month data from the ongoing U.S. Food and Drug Administration (FDA) Phase III registration trial with Urocidin(TM) for non-muscle-invasive bladder cancer refractory to current therapy are undergoing thorough analysis. Endo expects to complete this process by the end of September, 2010.

In North America, bladder cancer is the fourth most common cancer in men and is in the top ten for women. In the United States, approximately 70,000 patients are newly diagnosed with bladder cancer each year and 500,000 living patients have been affected. The cancers of many of the previously-diagnosed patients remain unresolved, sometimes leading to cystectomy (bladder removal) or death. Approximately 70 percent of bladder cancer patients have the non-muscle-invasive form of bladder cancer and, on appropriate regulatory approvals, might be eligible for multiple treatments with Urocidin(TM).

Non-muscle-invasive bladder cancer is a form of bladder cancer localized in the surface layers of the bladder that has not yet spread into the deeper muscle layer. This form of bladder cancer is treated predominantly by urologists using surgical resection and intravesical infusion therapy. Urocidin(TM) is an intravesical infusion therapy, administered via trans-urethral catheter into the bladder.

Under the licensing agreement, Bioniche received an up-front payment of US$20 million in July, 2009, and has the potential to receive a total of US$110 million in payments associated with the achievement of certain clinical, regulatory and commercial milestones. Three milestones have been achieved by the Company since November, 2009, for total proceeds of US$14 million. Future milestones will be announced as they are achieved and, with its exclusive manufacturing supply contract, Bioniche will also receive a net-sales-based revenue stream upon product approval.


----------------------------------------------------

from bladder cancer forum ....

Lowered dose BCG - so far so good - Bladder Cancer Support Forum

Re:Lowered dose BCG - so far so good 3 Months, 1 Week ago

Hi Alan
Bioniche is the sponsor of our Canadian bladder cancer network website.
www.cbcan.org
The trials are continuing in phase 111. Should have some preliminary results late this year.
Results comparing their product directly vs BCG will be a few years away.
Phase 111 trials are BCG refractory patients.
I can tell you that the people I know at Bioniche are extremely positive about their product.
When I hear more information I will post.
Ja

Great Market Stock! With an impressive stock picks record gainer at 276%. Check it out now.

h o t t e s t p i c k s . n e t

Note: Copy and Paste the link above into the browser without the spaces to get more information.

Good News ...BREAKOUT IS COMING !!!

Bioniche & University of Ottawa Sign Exclusive Global License Agreement for Natural Health Technology - Yahoo! Finance
Bioniche & University of Ottawa Sign Exclusive Global License Agreement for Natural Health Technology

Press Release Source: Bioniche Life Sciences Inc. On Wednesday August 25, 2010, 7:00 am

- potential animal health and human health applications for reduction of anxiety -

Bioniche is the next takeover candidate !!!!


Endo Pharmaceuticals Looks For Acquisitions - Yahoo! Finance

Endo Pharmaceuticals Looks For Acquisitions
On Friday August 27, 2010, 4:40 pm EDT

To broaden its product base, Endo has also done some in-licensing. In July, 2009, Endo acquired exclusive rights from Bioniche Life Sciences to develop and market phase-three drug Urocidin for bladder cancer in the U.S. with a global marketing option.

Having bought Penwest, Endo can now make all the decisions about Opana without consultation. It also won't need to pay Penwest the 22% in royalties that were part of the previous partnership deal.

Be dazzled with the #1 Canadian penny stocks newsletter.

__________________
Subscribe Now!